Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Public ClinicalTrials.gov record NCT00039130. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Study Of Rituximab And Short Duration, High Intensity Chemotherapy With G-CSF Support In Previously Untreated Patients With Burkitt Lymphoma/Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the numbers of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Combining chemotherapy with rituximab and filgrastim may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab with chemotherapy and filgrastim in treating patients who have Burkitt's lymphoma or Burkitt's leukemia.
Study identification
- NCT ID
- NCT00039130
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 105 participants
Conditions and interventions
Interventions
- filgrastim Biological
- rituximab Biological
- cyclophosphamide Drug
- cytarabine Drug
- dexamethasone Drug
- doxorubicin hydrochloride Drug
- etoposide Drug
- ifosfamide Drug
- leucovorin calcium Drug
- methotrexate Drug
- prednisone Drug
- vincristine sulfate Drug
- Allopurinol Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2002 (Type not available)
- Primary completion
- Sep 2010 (Actual)
- Completion
- Oct 2014 (Actual)
- Last update posted
- Aug 21, 2023
2002 – 2014
United States locations
- U.S. sites
- 31
- U.S. states
- 17
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Naval Medical Center - San Diego | San Diego | California | 92134 | — |
| Tunnell Cancer Center at Beebe Medical Center | Lewes | Delaware | 19958 | — |
| CCOP - Christiana Care Health Services | Newark | Delaware | 19713 | — |
| Walter Reed Army Medical Center | Washington D.C. | District of Columbia | 20307-5001 | — |
| University of Illinois Cancer Center | Chicago | Illinois | 60612-7243 | — |
| University of Chicago Cancer Research Center | Chicago | Illinois | 60637-1470 | — |
| Fort Wayne Medical Oncology and Hematology | Fort Wayne | Indiana | 46845 | — |
| Hematology Oncology Associates of the Quad Cities | Bettendorf | Iowa | 52722 | — |
| Holden Comprehensive Cancer Center at University of Iowa | Iowa City | Iowa | 52242-1002 | — |
| Greenebaum Cancer Center at University of Maryland Medical Center | Baltimore | Maryland | 21201 | — |
| Union Hospital Cancer Program at Union Hospital | Elkton | Maryland | 21921 | — |
| Masonic Cancer Center at University of Minnesota | Minneapolis | Minnesota | 55455 | — |
| Ellis Fischel Cancer Center at University of Missouri - Columbia | Columbia | Missouri | 65203 | — |
| Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756-0002 | — |
| Cancer Institute of New Jersey at Cooper - Voorhees | Voorhees Township | New Jersey | 08043 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263-0001 | — |
| Monter Cancer Center of the North Shore-LIJ Health System | Lake Success | New York | 11042 | — |
| CCOP - North Shore University Hospital | Manhasset | New York | 11030 | — |
| Don Monti Comprehensive Cancer Center at North Shore University Hospital | Manhasset | New York | 11030 | — |
| Long Island Jewish Medical Center | New Hyde Park | New York | 11040 | — |
| Stony Brook University Cancer Center | Stony Brook | New York | 11794-9446 | — |
| Presbyterian Cancer Center at Presbyterian Hospital | Charlotte | North Carolina | 28233-3549 | — |
| Duke Comprehensive Cancer Center | Durham | North Carolina | 27710 | — |
| Wayne Memorial Hospital, Incorporated | Goldsboro | North Carolina | 27534 | — |
| Wake Forest University Comprehensive Cancer Center | Winston-Salem | North Carolina | 27157-1096 | — |
| Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center | Columbus | Ohio | 43210-1240 | — |
| Rhode Island Hospital Comprehensive Cancer Center | Providence | Rhode Island | 02903 | — |
| Miriam Hospital | Providence | Rhode Island | 02906 | — |
| Mountainview Medical | Berlin Corners | Vermont | 05602 | — |
| Fletcher Allen Health Care - University Health Center Campus | Burlington | Vermont | 05401 | — |
| Virginia Commonwealth University Massey Cancer Center | Richmond | Virginia | 23298-0037 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00039130, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2023 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00039130 live on ClinicalTrials.gov.